Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies. (14th October 2020)

• Record Type: Journal Article
• Authors: McCaw, Zachary R; Tian, Lu; Kim, Dae Hyun; Localio, A Russell; Wei, Lee-Jen
• Is Part Of: Clinical infectious diseases. Volume 72:Number 11(2021)
• Page Start: e887
• Page End: e889
• Publication Date: 2020-10-14
• Subjects: mean survival time -- hazard ratio -- survival rate -- critical care -- dexamethasone; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1563
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.